Revolutionary plasma pen: Greifswald start-up receives million-dollar investment!

Revolutionary plasma pen: Greifswald start-up receives million-dollar investment!

The Greifswald-based medical technology company Neoplas Med is receiving a strong financial boost: The Japanese Niterra Group is investing a total of 24 million euros in the company, which is intended to promote the healing of wounds through innovative plasma technology. Managing Director Ulrike Sailer reports that the fresh capital, in particular an increase of 17 million euros, will be used to accelerate international expansion and further develop the technology platform for the treatment of chronic and infected wounds. The Plasma Pen, a groundbreaking tool, uses cold argon plasma to treat wounds and is said to significantly accelerate healing Baltic Sea newspaper reported.

Plasma technology in healthcare

Since its founding in 2009, Neoplas Med has established itself as a leading provider of cold plasma-assisted therapies. The company is developing its kINPen® MED, which aims precise plasma jets at wounds to accelerate healing by up to 50 percent. This technology allows treatment without skin contact and without side effects. The Niterra Ventures Company sees great potential in this innovation, which is reflected in the level of investment. Loud FinSMEs The financing will also be used to open up new markets in the USA, Europe and the Middle East.

Although Neoplas Med is growing, the company is not currently making a profit. Managing director Sailer points out that growth and the development of new technologies require capital, similar to other large companies in the industry. Up to 30 people are expected to be employed in Greifswald by the end of the year, a sign of the increasing interest in this revolutionary treatment method. The plasma pen could soon become standard in clinics, significantly improving care for patients with acute and chronic wounds.